InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 191161

Tuesday, 09/23/2014 8:20:24 PM

Tuesday, September 23, 2014 8:20:24 PM

Post# of 345846
Hakan Mellstedt : Peregrine Pharmaceuticals KOL :


Jafar Mahmoudian

Current position

2006 to date, Research Associate, Immunochemistry department, Monoclonal
Antibody Research Center, Avicenna Research Institute.
Advisor: Dr. Mahmoud Jeddi-Tehrani
(E-mail: mahjed@yahoo.com)
Current activity

Cancer Immunotherapy

Currently, one of our main interests is trying to acquire specific vaccines for various cancers in collaboration with Karolinska institute. Owing to side-effects traits of famous antibodies like Herceptin antibody; we are going to find alternative ones.

http://www.avicenna.ac.ir/Documents/CV/mahmoudian.pdf




Ok.... digging deeper, we have Advisor: Dr. Mahmoud Jeddi-Tehrani, tied directly into Peregrine KOL Hakan Mellstedt:
If you look at the publications... Hakan Mellstedt is all over the place with Dr Mahmoud Jeddi-Tehrani, and Dr. Jeddi-Tehrani has roots back in Karolinska, home of Hakan Mellstedt

Administration
. Head of diagnostic lab of Iran University of medical science.
. Head of Department of Immunology, Avesina Research Center.
. Head of Monoclonal Antibody Research Center.
. Member of Medical Biotechnology board of Iran.

http://www.avicenna.ac.ir/Documents/CV/tehrani.pdf




Is that enough to clearly show that Peregrine has some form of direct/indirect collaborations, stem cell research/vaccines..etc ?

Well that first profile above: Jafar Mahmoudian

5.Production of Monoclonal Antibody against Human Nestin
Reza Hadavi , Amir Hassan Zarnani , Negah Ahmadvand , Ahmad Reza Mahmoudi ,Ali Ahmad Bayat, Jafar Mahmoudian, Mohammad Reza Sadeghi , Haleh Soltanghoraee , Mohammad Mehdi Akhondi, Majid Tarahomi , Mahmood Jeddi-Tehrani , Hodjattallah Rabbani, Avicenna Journal of Medical Biotechnology, Vol. 2, Issue 2 (2010), 69 - 77

http://www.avicenna.ac.ir/Documents/CV/mahmoudian.pdf



well... it looks like I possibly found the connections to the many "followers" of Peregrine from this region of the world, which was puzzling for a bit, but its interesting how many follow very few Big Pharma... but decide to track Peregrine

Everyone follows and tracks for a reason, even everyone on this board. What a wonderful puzzle we have here... : )

Keep Calm and May the (Jeddi) Force Be With You....

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News